SCHEMBL8417806

SCHEMBL8417806

CC(C)(C)OC(=O)N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 8/20 0.59
THRA P10827 6/20 0.59
PPARG P37231 6/20 0.59
MEN1 O00255 5/20 0.59
KMT2A Q03164 5/20 0.59
LMNA P02545 4/20 0.59
TTR P02766 2/20 0.59
ADORA3 P0DMS8 2/20 0.59
PDE4D Q08499 2/20 0.59
HSD17B10 Q99714 2/20 0.59
RXRA P19793 2/20 0.59
NR1I2 O75469 2/20 0.59
NR3C1 P04150 1/20 0.59
CYP1A2 P05177 1/20 0.59
HTR1A P08908 1/20 0.59
CYP2C9 P11712 1/20 0.59
TBXA2R P21731 1/20 0.59
NTSR1 P30989 1/20 0.59
HTR2B P41595 1/20 0.59
USP2 O75604 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1526069 1.00 THRB (0.59) THRBTHRAPPARGMEN1KMT2A
SCHEMBL10780803 1.00 THRB (0.59) THRBTHRAPPARGMEN1KMT2A
SCHEMBL18558000 0.96 THRB (0.55) THRBTHRAPPARGMEN1KMT2A
Ethylenediamine SCHEMBL11090366 0.96 THRB (0.57) THRBTHRAPPARGMEN1KMT2A
Putrescine SCHEMBL11092650 0.94 THRB (0.55) THRBTHRAPPARGMEN1KMT2A
SCHEMBL10780866 0.93 THRB (0.57) THRBTHRAPPARGMEN1KMT2A
SCHEMBL12808939 0.91 THRB (0.56) THRBTHRAPPARGMEN1KMT2A
SCHEMBL13952218 0.91 ACE (0.50) THRBTHRAPPARGMEN1KMT2A
SCHEMBL21243772 0.91 ACE (0.58) PPARGITGB3ITGAVACEITGA2B
SCHEMBL5160323 0.91 ACE (0.58) PPARGITGB3ITGAVACEITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250325508-A1 MODULATORS OF PROTEASOME DYNAMICS AND/OR FUNCTION, COMPOSITIONS, METHODS, AND THERAPEUTIC USES THEREOF TECHNION RES & DEV FOUNDATION (IL) 2025-10-23 US disclosed
EP-4618968-A1 MODULATORS OF PROTEASOME DYNAMICS AND/OR FUNCTION, COMPOSITIONS, METHODS, AND THERAPEUTIC USES THEREOF Technion Research & Development Foundation Limited (IL) 2025-09-24 EP disclosed
WO-2024105677-A1 MODULATORS OF PROTEASOME DYNAMICS AND/OR FUNCTION, COMPOSITIONS, METHODS, AND THERAPEUTIC USES THEREOF TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2024-05-23 WO disclosed
CN-117279663-A Antibody drug conjugate comprising antibody against human CLDN18.2 and use thereof 乐高化学生物科学股份有限公司 2023-12-22 CN disclosed
CN-116406294-A Tyrosine, tryptophan and phenylalanine as mTOR agonists modulating proteasome kinetics, compositions, methods and uses thereof in therapy, and methods of prognosis of drug resistance 技术研发基金会有限公司 2023-07-07 CN disclosed
EP-4178563-A1 TYROSINE, TRYPTOPHAN AND PHENYLALANINE AS MTOR AGONISTS MEDIATING PROTEASOME DYNAMICS, COMPOSITIONS, METHODS AND USES THEREOF IN THERAPY, AND PROGNOSTIC METHODS FOR DRUG-RESISTANCE Technion Research & Development Foundation Ltd. (IL) 2023-05-17 EP disclosed
WO-2023078464-A1 EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF 上海弼领生物技术有限公司 2023-05-11 WO disclosed
WO-2022185319-A1 UBIQUITIN LIGASE KPC1-PEPTIDE BASED PROTEOLYSIS TARGETING CHIMERAS (PROTAC) AND USES THEREOF TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2022-09-09 WO disclosed
EP-1105730-B1 ENZYME INHIBITION IMMUNOASSAY ROCHE DIAGNOSTICS OPERATIONS (US) 2008-01-23 EP disclosed
US-5986094-A XANTHENE DYES AND PHTHALEIN DYES FOR FLUORESCEENT DYES ROCHE DIAGNOSTICS CORPORATION (US) 1999-11-16 US disclosed
US-4786591-A HETEROGENEOUS IMMUNOASSAY BOEHRINGER MANNHEIM GMBH (DE) 1988-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250325508-A1 MODULATORS OF PROTEASOME DYNAMICS AND/OR FUNCTION, COMPOSITIONS, METHODS, AND THERAPEUTIC USES THEREOF PSMC1, PSME3, PSMA6 THRB 2147/4885THRA 3519/4885PPARG 3376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.